Navigation Links
The First QPatch HT in China Placed in WuXi PharmaTech (NYSE: WX)
Date:5/21/2008

SHANGHAI, China, May 21 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), a leading pharmaceutical, biotechnology and medical device research and development outsourcing company with operations in China and the United States, announced today that it has acquired a QPatch HT automated patch clamp system, the first unit introduced into China by Sophion Bioscience.

The drug discovery process in pharmaceutical companies begins with identifying potential targets for new diseases. One important class of targets is ion channels that regulate the flow of ions across cellular membranes and therefore influence the physiology of all cells. Patch clamp is a widely applied gold-standard technique for the study of ion channels. Speed and accuracy of automated patch clamp systems are heavily demanded by pharmaceutical companies working with development of ion channel-based drugs.

The newly introduced QPatch HT is the world's first 48-channel gigaseal patch clamp system that can be applied to both voltage-gated and ligand-gated ion channels. With its ability to generate thousands of high-quality data points daily, QPatch HT is enabling new screening paradigms in ion channel drug discovery and safety testing on a truly industrial basis. It is claimed to be taking automated patch clamping to a new and even more powerful level.

"We hope the acquisition of the QPatch technology will assist WuXi PharmaTech in expanding their services into the rapidly increasing fields of cardiac safety testing and ion channel drug discovery," commented Frank Henrichsen, Vice President Sales and Marketing in Sophion Bioscience, the supplier of QPatch HT.

"We are very pleased to have installed the first QPatch HT automated patch clamp system in China, and indeed, the first ever such unit in any integrated drug and medical device R&D outsourcing service company," Dr. Peng Wang, Vice President of Discovery Biology at WuXi PharmaTech, said excitedly, "It will greatly enhance our drug R&D service capabilities and productivity. We will continue investing in cutting-edge discovery technologies as we strive to serve our global clients better."

About WuXi PharmaTech

WuXi PharmaTech is a leading pharmaceutical, biotechnology and medical device R&D outsourcing company, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides pharmaceutical, biotechnology and medical device companies a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. For more information, please visit: http://www.wuxipharmatech.com .


'/>"/>
SOURCE WuXi PharmaTech
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Crdentia Announces 2008 First Quarter Results
2. DaVita Renal Dietitians Conduct First-Ever EYE on CKD Workshop
3. Cord Blood America Reports First Quarter Financial Results; Gross Profits Increase
4. The Childrens Hospital of Philadelphia Opens the Worlds First Delivery Unit for Mothers Diagnosed with Birth Defects in Fetus
5. Shamir Optical Industry Ltd. to Host Conference Call Announcing First Quarter 2008 Earnings Results
6. First-born babies higher asthma and allergy rates due to pregnancy conditions
7. Baker Energy and Huber Receive First-of-its-Kind Award from Wyoming Department of Environmental Quality
8. Population Health Impact Institute to Host First Methods Evaluation Process(TM) (MEP(TM)) Workshop at Annual CMSA Conference
9. AMDL Announces Teleconference and Audio Web Conference to Discuss First Quarter Financial Results
10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
11. BMP Sunstone Reports First Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... ... February 12, 2016 , ... Fixed Dose Combination Drug ... p.m. EST, http://www.fdanews.com/fixeddosecombination , Fixed dose combination products ... increased attention from all stakeholders in the development of new chemical entities. , ...
(Date:2/12/2016)... , ... February 12, 2016 , ... ... Leadership Series at Zuckerberg San Francisco General Hospital on April 5-7. The series ... behaviors and create new habits. The workshops cover a broad range of topics, ...
(Date:2/12/2016)... , ... February 12, 2016 , ... The Jones Agency, ... communities across eastern Texas, is launching a cooperative charity drive with the Tarrant Area ... Serving more than 50,000 individuals and families in need, the Tarrant County Food Bank ...
(Date:2/12/2016)... ... ... Miami Dental Specialists is excited to bring patients the choice of ceramic, ... Dental Specialists will offer the non-metal implants as a safe, holistic and hygienic approach ... the dental implant manufacturer, Straumann, to bring this cutting-edge technology to Miami. ...
(Date:2/12/2016)... ... 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased ... upcoming Feb. 24 webinar that will discuss ways health plans and PBMs are ... the $1,000-per-pill hepatitis C treatment Sovaldi and high-cost PCSK9 inhibitors to treat cholesterol. ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Calif. , Feb. 12, 2016  SI-BONE, Inc., a medical ... ® ("iFuse"), a minimally invasive surgical (MIS) device indicated for ... National Government Services, Inc. (NGS), the Medicare Administrative Contractor (MAC) covering ... , Maine , Massachusetts ... , New York , Rhode Island ...
(Date:2/12/2016)... Calif. , Feb. 12, 2016  Sequent Medical, ... in a study to evaluate the safety and effectiveness ... the treatment of ruptured intracranial aneurysms.  Prof Laurent ... Hospital, in Paris, France and ... patient. France and Germany.  ...
(Date:2/12/2016)... Lilly and Company (NYSE: LLY ) today announced that ... regimen patent would not presently be infringed by Actavis marketing ... Italy and Spain ... solution.  --> --> ... that Lilly,s patent would be indirectly infringed by Actavis marketing ...
Breaking Medicine Technology: